Improving P. Aeruginosa Detection With Breath-based Diagnostics (IMPACT-Breath)

Last updated: December 2, 2023
Sponsor: University of British Columbia
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cystic Fibrosis

Lung Disease

Treatment

N/A

Clinical Study ID

NCT04735952
331178/ H20-00071
R56HL139846
Pro00043176
HILL18A0
  • Ages > 3
  • All Genders

Study Summary

The study is a breath biomarker validation study. It is anticipated that 300 patients with cystic fibrosis (CF) from 5 clinical sites in the USA will be enrolled. The study is funded by the US NIH and the US Cystic Fibrosis Foundation. Enrollment commenced in May 2019. Sputum, induced sputum, and oropharyngeal swabs will be collected and evaluated at each clinic as part of standard clinical practice. Excess sputum will be sent to Children's Colorado Hospital for molecular analysis. No swabs will be sent anywhere (other than the clinic from which they originate). Breath samples will be taken from all study participants.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Aim 1, Cross-Sectional IInclusion Criteria:
  1. Male or female, ages 8 years and older
  2. Diagnosis of CF based on sweat chloride ≥ 60 mmol/L and/or 2 known CF mutations
  3. @ BC Children's Hospital only- Non-expectorators are eligible if having a clinicallyindicated OP swab.
  4. FEV1 ≥ 30% predicted for spontaneous expectorators or FEV1 ≥ 40% predicted forsubjects undergoing sputum induction
  5. Either P. aeruginosa (Pa) negative or chronically infected with P. aeruginosa (Papositive) as defined below: a. P. aeruginosa negative: must meet one of the following criteria: i: No growth of Pain previous 12 months and ≥ 4 consecutive Pa-negative cultures, OR ii: No history ofPa positive airway cultures (sputum, OP, Bronchoalveolar lavage) b. P. aeruginosapositive i: Over 50% of cultures positive and at least 2 cultures positive for Pa inprevious 18 months
  6. Willing to participate in and comply with the study procedures and willingness of thesubject, parent or legally authorized representative to provide written informedconsent.

Exclusion

Exclusion criteria:

  1. Age < 8 years
  2. Intermittently infected with Pa
  3. FEV1 < 30%
  4. History of lung transplant
  5. Presence of a condition or abnormality that in the opinion of the PrincipalInvestigator would compromise the safety of the subject or the quality of the data. Aim 2, Longitudinal Inclusion Criteria, Expectorating Cohort (n=48):
  6. Male or female, ages 8-16 years
  7. Diagnosis of CF based on sweat chloride ≥ 60 mmol/L and/or 2 known CF mutations
  8. @ BC Children's Hospital only- Non-expectorators are eligible if having a clinicallyindicated OP swab.
  9. FEV1 ≥ 30% predicted for spontaneous expectorators or FEV1 ≥ 40% predicted forsubjects undergoing sputum induction
  10. P. aeruginosa negative, based on one of the following criteria:
  11. No growth of Pa in previous 12 months and ≥ 4 consecutive Pa-negative cultures
  12. No history of Pa positive airway cultures (sputum, OP, bronchoalveolar lavage)
  13. Willing to participate in and comply with the study procedures and willingness of thesubject, parent or legally authorized representative to provide written informedconsent. Exclusion criteria:
  14. Age < 8 years
  15. Intermittently or chronically infected with Pa
  16. Unable to expectorate sputum or undergo sputum induction
  17. FEV1 < 30%
  18. History of lung transplant
  19. Presence of a condition or abnormality that in the opinion of the PrincipalInvestigator would compromise the safety of the subject or the quality of the data. Inclusion Criteria, Non-Expectorating Cohort (n=10):
  20. Male or female, ages 3-8 years
  21. Diagnosis of CF based on sweat chloride ≥ 60 mmol/L and/or 2 known CF mutations 3.FEV1 ≥ 30%
  22. Unable to expectorate sputum 5. P. aeruginosa negative, based on one of the followingcriteria:
  23. No growth of Pa in previous 12 months and ≥ 4 consecutive Pa-negative cultures
  24. No history of Pa positive airway cultures (sputum, OP, bronchoalveolar lavage) 6.Willing to participate in and comply with the study procedures and willingness of thesubject, parent or legally authorized representative to provide written informedconsent. Exclusion criteria:
  25. Age < 3 years
  26. Intermittently or chronically infected with Pa
  27. FEV1 < 30%
  28. History of lung transplant
  29. Presence of a condition or abnormality that in the opinion of the PrincipalInvestigator would compromise the safety of the subject or the quality of the data.

Study Design

Total Participants: 300
Study Start date:
May 03, 2019
Estimated Completion Date:
December 31, 2024

Study Description

AIM 1: Refine and validate volatile biomarkers in the breath of adult and pediatric CF patients for detecting established P. aeruginosa lung infections. For each expectorating subject (n ≥ 288; 5 centers), the diagnostic accuracy of the volatile biomarker panel will be tested, with sputum culture as the standard.

AIM 2: Quantify intra-subject breath variability of the target pediatric population. We will collect longitudinal breath samples for two years from P. aeruginosa-negative subjects (n ≥ 58; ~60% non-expectorating) at 4 pediatric CF clinical centers. We will measure intra-subject variance in the breath signatures of expectorating and non-expectorating subjects, with the latter being the target population for the clinical trial. Two to 8 breath samples will be collected per patient.

Connect with a study center

  • BC Children's Hospital

    Vancouver, British Columbia V6H3N1
    Canada

    Active - Recruiting

  • St. Paul's Hospital

    Vancouver, British Columbia V6Z1Y6
    Canada

    Active - Recruiting

  • Phoenix Children's Hospital

    Phoenix, Arizona 85016
    United States

    Completed

  • Children's Hospital Colorado

    Aurora, Colorado 80045
    United States

    Completed

  • National Jewish Health

    Denver, Colorado 80206
    United States

    Completed

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire 03756
    United States

    Site Not Available

  • Cincinnati Children's Hospital

    Cincinnati, Ohio 45229-3039
    United States

    Completed

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.